Evidence map›Paper›PMID 36479670›Full record

ArticleJournal of thrombosis and thrombolysis2023

Evaluation of the effect of eltrombopag therapy on the platelet collagen receptor glycoprotein VI (GPVI) expression and soluble GPVI levels in young patients with immune thrombocytopenia.

Azza Abdel Gawad Tantawy, Nayera Hazaa Khalil Elsherif, Fatma Soliman Ebeid, Rasha Abd El-Rahman El-Gamal, Eman Abdel Rahman Ismail, Mahmoud A Kenny, Michael Botros Elkes Morcos

Open access · hybridFull text read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of thrombosis and thrombolysis, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.5field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 3 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Azza Abdel Gawad TantawyPediatrics Department, Faculty of Medicine, Ain Shams University, Cairo, Egypt.
Nayera Hazaa Khalil ElsherifPediatrics Department, Faculty of Medicine, Ain Shams University, Cairo, Egypt. elsherif.nayera@gmail.com.ORCID http://orcid.org/0000-0002-7249-7971
Fatma Soliman EbeidPediatrics Department, Faculty of Medicine, Ain Shams University, Cairo, Egypt.
Rasha Abd El-Rahman El-GamalClinical Pathology Department, Faculty of Medicine, Ain Shams University, Cairo, Egypt.
Eman Abdel Rahman IsmailClinical Pathology Department, Faculty of Medicine, Ain Shams University, Cairo, Egypt.
Mahmoud A KennyPediatrics Department, Faculty of Medicine, Ain Shams University, Cairo, Egypt.
Michael Botros Elkes MorcosPediatrics Department, Faculty of Medicine, Ain Shams University, Cairo, Egypt.
Ain Shams University · EG

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundPlatelet glycoprotein VI (GPVI) receptor is essential for platelet adhesion and aggregation. Eltrombopag is as an effective treatment for chronic immune thrombocytopenia (ITP); yet, its effect on platelet function is not fully characterized.

aimThis prospective study investigated the effect of eltrombopag therapy on platelet function through assessment of GPVI receptor expression and soluble GPVI levels among pediatric patients with persistent or chronic ITP.

methodsThirty-six children and adolescents with persistent or chronic ITP were divided equally into two groups either to receive eltrombopag therapy or the standard of care. All patients were followed-up for 12 months with assessment of bleeding score and complete blood count (CBC). Evaluation of GPVI expression using flow cytometry and measurement of its soluble form by ELISA was done at baseline and at 6 months.

resultsITP patients on eltrombopag had significantly lower bleeding score after 6 months of therapy while the quality of life has significantly improved. Platelet count was significantly increased throughout the study. GPVI expression by flow cytometry and soluble GPVI levels were significantly increased after eltrombopag therapy. After 12 months, ITP patients on eltrombopag were able to maintain a good quality of life and low bleeding score.

conclusionOur data suggest that eltrombopag, through its effect on the GPVI receptor expression and its soluble form, might reduce bleeding manifestations and improve the quality of life of chronic and persistent ITP children independent of its effect on the platelet count.

Indexed as

Purpura, Thrombocytopenic, IdiopathicThrombocytopeniaAdolescentBenzoatesChildHemorrhageHumansHydrazinesPlatelet Membrane GlycoproteinsProspective StudiesPyrazolesQuality of LifeBenzoateseltrombopagHydrazinesPlatelet Membrane Glycoproteinsplatelet membrane glycoprotein VIPyrazolesChronic ITPEltrombopagGPV1 receptor expressionSoluble GPV1

Identifiers

PMID36479670
PMCPMC10011314
OpenAlexW4310943586

What OpenQuestion holds

Textfull text, public
LicenceCC BY
measurements read17
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.